A Stock Analysis: Agilent Technologies | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 36.911m USD | 12M Return: 9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 297M
EPS Trend: 47.9%
Qual. Beats: 1
Rev. Trend: 39.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Agilent Technologies (NYSE: A) is a U.S.-based provider of application-focused analytical instruments, software, and services for the life sciences, diagnostics, and applied chemical markets, operating through three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Its core offerings span liquid chromatography, mass spectrometry, gas chromatography, spectroscopy, genomics, and laboratory automation/robotics, sold both directly and through distributors, resellers, manufacturers representatives, and e-commerce channels.
The company sits within the Life Sciences Tools & Services sub-industry, where it competes with peers such as Danaher, Thermo Fisher Scientific, and Waters; the bulk of demand is driven by pharmaceutical R&D, biotech, clinical diagnostics, and academic/government research labs, which tend to produce recurring revenue through consumables, service contracts, and software subscriptions layered on top of installed instruments. The CrossLab segment is the primary vehicle for this recurring-services and consumables model, bundling repairs, compliance, training, asset management, and informatics (including the OpenLab platform) with column and consumable supply.
Agilent was incorporated in 1999 and is headquartered in Santa Clara, California, and is classified as a large-cap stock within the Health Care sector.
- Biopharma LC-MS demand drives Life Sciences segment revenue growth
- CrossLab services and consumables expand recurring high-margin revenue
- China revenue exposure creates tariff and geopolitical headwind risk
| Net Income: 1.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.17 > 1.0 |
| NWC/Revenue: 34.49% < 20% (prev 33.13%; Δ 1.35% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.45b > Net Income 1.41b |
| Net Debt (1.55b) to EBITDA (1.96b): 0.79 < 3 |
| Current Ratio: 2.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.0m) vs 12m ago -0.35% < -2% |
| Gross Margin: 53.00% > 18% (prev 53.35%; Δ -0.35% > 0.5%) |
| Asset Turnover: 57.34% > 50% (prev 54.52%; Δ 2.83% > 0%) |
| Interest Coverage Ratio: 16.05 > 6 (EBIT TTM 1.69b / Interest Expense TTM 105.0m) |
| A: 0.19 (Total Current Assets 4.76b - Total Current Liabilities 2.27b) / Total Assets 13.1b |
| B: 0.13 (Retained Earnings 1.69b / Total Assets 13.1b) |
| C: 0.13 (EBIT TTM 1.69b / Avg Total Assets 12.6b) |
| D: 1.20 (Book Value of Equity 7.12b / Total Liabilities 5.94b) |
| Altman-Z'' = 3.83 = AA |
| DSRI: 1.01 (Receivables 1.50b/1.37b, Revenue 7.23b/6.63b) |
| GMI: 1.01 (GM 53.35% / 53.00%) |
| AQI: 0.96 (AQ_t 0.47 / AQ_t-1 0.50) |
| SGI: 1.09 (Revenue 7.23b / 6.63b) |
| TATA: -0.00 (NI 1.41b - CFO 1.45b) / TA 13.1b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 134.29 with a total of 1,754,483 shares traded. Over the past week, the price has changed by +2.75%, over one month by +2.22%, over three months by +16.94% and over the past year by +9.02%.
Current recommended Stop Loss: 124.80 (which is 7.1% or 2.3 ATR below the current price).
Agilent Technologies has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy A.
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 160.3 | 19.4% |
P/E Trailing = 26.243
P/E Forward = 19.8413
P/S = 5.1038
P/B = 5.2898
P/EG = 1.1815
Revenue TTM = 7.23b USD
EBIT TTM = 1.69b USD
EBITDA TTM = 1.96b USD
Long Term Debt = 3.05b USD (from longTermDebt, last quarter)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.55b USD (calculated: Debt 3.35b - CCE 1.81b)
Enterprise Value = 38.5b USD (36.9b + Debt 3.35b - CCE 1.81b)
Interest Coverage Ratio = 16.05 (Ebit TTM 1.69b / Interest Expense TTM 105.0m)
EV/FCF = 30.62x (Enterprise Value 38.5b / FCF TTM 1.26b)
FCF Yield = 3.27% (FCF TTM 1.26b / Enterprise Value 38.5b)
FCF Margin = 17.37% (FCF TTM 1.26b / Revenue TTM 7.23b)
Net Margin = 19.55% (Net Income TTM 1.41b / Revenue TTM 7.23b)
Gross Margin = 53.00% ((Revenue TTM 7.23b - Cost of Revenue TTM 3.40b) / Revenue TTM)
Gross Margin QoQ = 54.99% (prev 52.61%)
Tobins Q-Ratio = 2.94 (Enterprise Value 38.5b / Total Assets 13.1b)
Interest Expense / Debt = 3.13% (Interest Expense 105.0m / Debt 3.35b)
Taxrate = 10.51% (166.0m / 1.58b)
NOPAT = 1.51b (EBIT 1.69b * (1 - 10.51%))
Current Ratio = 2.10 (Total Current Assets 4.76b / Total Current Liabilities 2.27b)
Debt / Equity = 0.47 (Debt 3.35b / totalStockholderEquity, last quarter 7.12b)
Debt / EBITDA = 0.79 (Net Debt 1.55b / EBITDA 1.96b)
Debt / FCF = 1.23 (Net Debt 1.55b / FCF TTM 1.26b)
Total Stockholder Equity = 6.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.21% (Net Income 1.41b / Total Assets 13.1b)
RoE = 20.84% (Net Income TTM 1.41b / Total Stockholder Equity 6.79b)
RoCE = 17.13% (EBIT 1.69b / Capital Employed (Equity 6.79b + L.T.Debt 3.05b))
RoIC = 14.04% (NOPAT 1.51b / Invested Capital 10.7b)
WACC = 9.23% (E(36.9b)/V(40.3b) * Re(9.81%) + D(3.35b)/V(40.3b) * Rd(3.13%) * (1-Tc(0.11)))
Discount Rate = 9.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.28 | Cagr: -1.53%
[DCF] Terminal Value 73.20% ; FCFF base≈1.23b ; Y1≈1.29b ; Y5≈1.50b
[DCF] Fair Price = 65.62 (EV 20.1b - Net Debt 1.55b = Equity 18.5b / Shares 282.4m; r=9.23% [WACC]; 5y FCF grow 5.63% → 2.50% )
EPS Correlation: 47.93 | EPS CAGR: 1.69% | SUE: 3.09 | # QB: 1
Revenue Correlation: 39.21 | Revenue CAGR: 1.55% | SUE: 1.36 | # QB: 1
EPS current Quarter (2026-07-31): EPS=1.49 | Chg30d=-0.63% | Revisions=-18% | Analysts=16
EPS current Year (2026-10-31): EPS=6.06 | Chg30d=+1.50% | Revisions=+84% | GrowthEPS=+8.4% | GrowthRev=+7.2%
EPS next Year (2027-10-31): EPS=6.61 | Chg30d=+0.94% | Revisions=+25% | GrowthEPS=+9.1% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +43% (up=30, down=11)